anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Typical clinical rTMS treatment is delivered on the left dorsolateral prefrontal cortex (DLPFC) at a 10 Hz frequency for 30-45 minutes to increase cortical excitability which will outlast the duration of stimulation. The treatment involves daily sessions that are applied over a four to six-week period. Intermittent theta burst stimulation (iTBS) is a novel refinement of conventional rTMS. iTBS consists of bursts of 3 stimulations at 50 Hz at theta frequency (5 Hz). However, instead of 30-min treatment sessions, iTBS has comparable clinical efficacy with only 3 minutes treatment sessions. Because iTBS is a novel technique, much of its effects on the brain are currently unknown. However, since it is a modified rTMS protocol, it is assumed that its neuronal effects are comparable.

Therapeutic effects of rTMS are thought to be related to its effects on the subgenual anterior cingulate cortex (sgACC; Broadman area 25). In depression, metabolic activity of the sgACC is increased (measured as increase of 18F-labeled fluorodeoxyglucose (\[18F\]FDG) uptake with positron emission tomography (PET)). Importantly, the metabolic activity of the sgACC appears to be a general marker for treatment response, e.g. \[18F\]FDG uptake is decreased in response to antidepressant medications or deep brain stimulation. In addition to resting state functional MRI, diffusion weighted imaging has been used to study TMS targets, but this technique has never been used for testing targets for treating depression.

Currently, the system level mechanisms of action of iTBS in depression patients are completely unexplored. Based on prior research the investigators hypothesize that 1) a single session of iTBS will decrease \[18F\]FDG uptake in the sgACC and 2) the magnitude of decrease is related to the connectivity between the target site and the sgACC. This study will establish the system level mechanisms of action of iTBS, paving a way to improve clinical treatment. This study will also develop connectivity measures that can be used to improve iTBS targeting (i.e. choose iTBS target based on sgACC connectivity) and predict treatment response (i.e. predict iTBS treatment response in patients based on sgACC connectivity).
BACKGROUND: The school-age is a crucial period of physical and cognitive growth, which requires an assessment of dietary intake and its influence on body weight and height. This study aims to determine the association between the quality and quantity of carbohydrate intake with selected anthropometric indices in primary school girls in Kerman City, Iran.
METHODS: This cross-sectional study was conducted on 330 primary school girls ages 6-12 years in Kerman. We used a validated and reliable dish-based 185-item food frequency questionnaire to evaluate people's food intake. We assessed the amount of carbohydrates in children's diets as the percentage of daily calories and grams per day. We used dietary fiber intake (grams/day), the glycemic load, the ratio of whole grain to total grain, and the ratio of solid carbohydrates to total carbohydrates to assess carbohydrate quality. Height, weight, and arm circumference were measured. We calculated body mass index (BMI) by dividing the weight in kilograms by the height in centimeters squared. We used the World Health Organization z-scores charts for girls 5 to 19 years old to assess z-scores for BMI-for-age (BAZ), height-for-age (HAZ), and weight-for-age (WAZ). Socioeconomic status and physical activity were assessed. We used ANOVA and ANCOVA statistical tests to assess the association between anthropometric indices and carbohydrate quantity and quality parameters.
RESULTS: Participants with the highest amount of carbohydrate intake had significantly higher anthropometric indices, including arm circumference, BMI-for-age z score (BAZ), and Height-for-age z score (HAZ) (p < 0.001, p < 0.001, and p = 0.009, respectively). With the increase in glycemic load (GL) and dietary fiber intake, anthropometric indices including arm circumference (GL: p < 0.001, Fiber: p < 0.001), BAZ (GL: p < 0.001, Fiber: P < 0.001), and HAZ (GL: P = 0.009, Fiber: p < 0.001) increased significantly.
CONCLUSIONS: We concluded that there was a positive association between the amount of carbohydrate intake and anthropometric indices (MUAC, BAZ, and HAZ). Also, with the increase in glycemic load and dietary fiber intake, the anthropometric indices including MUAC, BAZ, and HAZ increased.
PURPOSE:To obtain the titled safe preparation useful for products necessary to be subjected to antibacterial treatment or antibacterial process, e.g. food, medicine, etc., by using a specific amount of a partially decomposed nucleoprotamine separated from soft-roe of fish. CONSTITUTION:The objective antibacterial preparation contains 5-100wt.% partially decomposed nucleoprotamine separated from soft-roe of fish (e.g. salmon, herring, bonito, trout, etc.). The partially decomposed nucleoprotamine is a compound produced by depolymerizing deoxyribonucleic acid with an enzyme, etc., and partially isolating deoxyribonucleic acid. The present preparation is composed mainly of a component produced by treating defatted soft-roe of fish with a nuclease such as deoxyribonuclease to depolymerize the nucleic acid optionally treating the product with an alkali and partially detaching and decomposing the nucleic acid. The degree of detachment of nucleic acid can be controlled mainly with the pH of the solution and the pH is usually 7-11.
A food alginate-encapsulated microcapsule encapsulates alginate (excluding sodium salt) as an active ingredient. The microcapsule encapsulates alginate such that alginate does not directly contact a tongue when the microcapsule is adhered or added to food. Thus, the food can be taken with no feeling of unique smell and flavor of alginate, specifically ammonium alginate. Direct salt adsorption due to alginate is prevented in the food so that the food can be taken without impairing salty taste. In addition, the microcapsule disintegrates in a gastrointestinal tract, and alginate exercises a sodium adsorption ability. Accordingly, sodium excretion is promoted.
To ascertain whether habitual green tea consumption is associated with sarcopenia among Japanese older adults, using the screening tool for sarcopenia (SARC-F). This cross-sectional study in Mukawa, Hokkaido, Japan, was conducted between June and September 2022 and included 364 Japanese participants older than 65 y. Habitual green tea consumption and energy intake were ascertained using a validated self-administered food frequency questionnaire. Sarcopenia was evaluated using the SARC-F. Multivariable logistic regression analysis was used to estimate the odds ratio (OR) and 95% confidence interval (CI) of sarcopenia risk across participant tertiles of green tea consumption, with adjustments for age, sex, body mass index, living alone, habitual exercise, walking hours, current smoking status, current alcohol consumption status, energy intake, protein intake, vegetable intake, and fruit intake. In this study of 364 participants (154 men and 210 women), the prevalence of sarcopenia risk was 9.3%. The multivariable-adjusted OR [95% CI] of green tea consumption for ≥1 cup/d compared with that of <1 cup/wk of sarcopenia was 0.312 [0.129-0.752]. Higher habitual green tea consumption was inversely associated with sarcopenia among Japanese older adults. Further longitudinal studies are required to confirm these findings.
Multifunctional compositions and methods are provided for therapeutic treatment of bacteria and cancers and for fluorescence diagnosis. Systems generate in situ reactive oxygen species such as singlet oxygen ( 1 O 2 ), hydroxyl radical (OH) and Juglone, and other chemotherapeutic agents. Methods provided selectively produce greater amounts of one reactive oxygen species over others. Variations are effective in aerobic, anaerobic or H 2 O 2  rich environments and in presence of, or absence of, light. In H 2 O 2  rich environment in absence of light, variations decompose H 2 O 2  into O 2  gas to remove excess H 2 O 2  for elimination of hypoxic environment. Variations are formed of porphyrins, naphthalene derivatives, and metal ions, for illustration, free base tetrakis Ar substituted porphyrine core without metal or halide substitution but having hydroxyphenyl and alkyl pyridyl substituents at meso positions combined with dihydroxynaphthalene and +3 hydrated metal ions.
PROBLEM TO BE SOLVED: To provide an immunoregulatory agent and an antiinflammatory agent each having stable immunoregulatory and anti-inflammatory activities and effective for autoimmune diseases, especially collagen disease, systemic lupus erythematous, chronic rheumatoid arthritis and the like. SOLUTION: This immunoregulatory agent and the antiinflammatory agent each contains the extract of Agaricus blazei Murr. as an ingredient. The Agaricus blazei Murr. is preferably Agaricus blazei Murr. CJ-01. The Agaricus blazei Murr. CJ-01 is covered with soil in a compost culture medium having a pH of 5.5-7.0, a water content of 55-80% and a C/N ratio of 25-95 and cultured under the irradiation of light.
This is a Phase I/II dendritic cell vaccine study for patients with prostate cancer. Our laboratory has demonstrated that effective tumor immunity in humans is associated with, and likely mediated at least in part by tumor antigen-specific killer T cells (Albert et al., 1998a; Darnell, 1999; Darnell and Posner, 2003). Moreover, we have demonstrated that apoptotic material derived from dying tumor cells are a potent means of delivering antigen to DCs and subsequently triggering tumor antigen-specific T cell responses ex vivo (Albert et al., 1998a; Albert et al., 1998c). In this study, patients with 3 consecutive rises in PSA measured at least 2 week apart, after definite local therapy (prostatectomy or radiation) will be recruited. Peripheral blood monocytes will be collected by leukapheresis and dendritic cells will be generated in the Cleanroom in the Laboratory of Molecular Neuro-Oncology. These dendritic cells will be pulsed with apoptotic prostate cancer cells from a cell line (LNCaP), harvested, tested for certain release criteria, and then injected as vaccine. When patients are found to be eligible for the study, they will be randomized into either the experimental group or the placebo group for the purposes of comparing adverse events between groups only. Vaccine plus 3 boosters (or placebo) will be given, each two weeks apart. After the third booster, patients will be unblinded. Those receiving the vaccine will when enter the follow up phase which includes a post treatment leukapheresis. Those in the placebo group will cross over and receive the vaccine and boosters. The primary outcomes to be evaluated are toxicity and activity. Patients will be evaluated for both local and systemic toxicity. For activity, we measure both immunological and clinical responses to the vaccine, comparing measures taken before and after vaccination, combining patients in both arms.
Anemia is sometimes seen in patients receiving NSAIDs, including ARTHROTEC. This may be due to fluid retention, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including ARTHROTEC, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia.

NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving ARTHROTEC who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants, should be carefully monitored.
Catapres‑TTS® is a multi-layered film, 0.2 mm thick, containing clonidine as the active agent. The system areas are 3.5 cm2 (Catapres‑TTS®‑1), 7.0 cm2 (Catapres‑TTS®‑2) and 10.5 cm2 (Catapres‑TTS®‑3) and the amount of drug released is directly proportional to the area (see Release Rate Concept). The composition per unit area is the same for all three doses.

Proceeding from the visible surface towards the surface attached to the skin, there are four consecutive layers: 1) a backing layer of pigmented polyester and aluminum film; 2) a drug reservoir of clonidine, mineral oil, polyisobutylene, and colloidal silicon dioxide; 3) a microporous polypropylene membrane that controls the rate of delivery of clonidine from the system to the skin surface; 4) an adhesive formulation of clonidine, mineral oil, polyisobutylene, and colloidal silicon dioxide. Prior to use, a protective slit release liner of polyester that covers the adhesive layer is removed.

Cross Section of the System:
The proposed project will enroll 90 subjects with probable DLB, 60 from Mayo Clinic Rochester (MCR) and 30 from Mayo Clinic Jacksonville (MCJ). Additionally, 45 controls will be enrolled, 30 from MCR and 15 from MCJ. We will obtain up to six assessments in each subject over the 5 years of the study, baseline, six month and annually thereafter. We will follow these cohorts with clinical and biospecimen data collection annually and once at six months, and CSF collection annually within the guidelines of the Parkinson's Disease Biomarker's Program (PDBP). Clinical neuroimaging will be performed annually and include: a) dopamine transporter imaging with Ioflupane (123I) SPECT (DaTscan) as the biomarker of LBD-related loss of dopaminergic activity, b) structural MRI AD- signature atrophy as the biomarker of AD-related neurodegeneration, c) β-amyloid (Aβ) deposition on PET as the biomarker of Aβ pathology. In patients from the MCR site, we will investigate AV-1451 PET. Since the specificity of AV-1451 PET is not established for tau deposition in DLB, we will investigate this biomarker in a subset of DLB patients to determine the pattern of AV-1451 uptake compared to clinically normal controls, and its association with atrophy, Aβ load and clinical disease progression in DLB.
American Academy of Pediatrics guidelines define the growth rate of preterm, underweight babies as adequate if it matches the age-equivalent weight gains typical of term infants, approximately 10-15 grams per kg per day. Unfortunately, many pre-terms, especially very low birth weight ones, do not achieve this rate, resulting in neurodevelopmental deficits and low discharge weights. Typical feeding regimens, designed to increase weight gain, however, have been shown to increase the rate of fat accretion and increase the risk of obesity and metabolic disorders, such as insulin resistance and type 2 diabetes, later in life. Research has shown that higher protein diets can reduce the accretion of body fat in older, normal weight infants but this has not been systematically tested in low birth weight pre-terms. The current study will compare weight gain based on fat accretion and change in body composition in preterm infants receiving higher (4g/100 kcal) versus lower (3 g/100 kcal) protein-energy ratio diets. The hypothesis tested in this study is: Increased protein intake will reduce the percentage of weight gain due to fat accretion in pre-term infants. The identification of an effective feeding regimen that would both allow pre-term infants to acquire age-equivalent growth rates similar to those of term infants while avoiding the excess accretion of body fat could significantly improve the long term health outcomes of this high-risk population.
In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the response and state entropy values between 40 and 60 from the start of anesthesia to the end of surgery. In the control group, dosage of volatile anesthetics will be titrated according to clinical judgment.
Participants who completed study SD-809-C-15 (NCT01795859, including 1-week washout period and Week 13 evaluation), will receive 6 milligrams (mg) SD-809 ER tablet once daily as a starting dose in this study. Dose titration will be continued through Week 8 to optimize dose. Dose of SD-809 ER can be adjusted weekly in increments of 6 milligrams per day (mg/day) (6 or 12 mg/day after a total daily dose of 48 mg is reached) based on chorea control and adverse events. Daily doses of SD-809 ER 12 mg and higher will be administered twice daily. Maximum total daily dose of SD-809 ER will be 72 mg/day (36 mg twice daily), unless participant is receiving a strong CYP2D6 inhibitor(such as, paroxetine, buproprion, fluoxetine), in which case maximum total daily dose will be 42 mg (21 mg twice daily). Long-term treatment with SD-809 ER at a stable dose (further dose adjustments are permitted, if clinically indicated) will be continued until SD-809 ER become commercially available in United States.
This is a multicenter prospective observational study that will collect data on \>1000 alive patients who have undergone PCI between 1 and 1.5 years prior at 9 hospitals from October 2018. Adult patients (aged ≥18 years) undergoing PCI and prescribed mono-antiplatelet agents (such as aspirin, dihydroxyaluminum aminoacetate-heavy magnesium carbonate-aspirin, and clopidogrel) are eligible for enrollment. In phase 1, patients will be investigated in a cross-sectional manner for the withdrawal rate of dual antiplatelet agents within 1 year after stent implantation. In phase 2, patients will be followed up at 1, 3, and 6 months for AI-GIS and other outcomes. The primary endpoint is AI-GIS (according to the Gastrointestinal Symptom Rating Scale score) or gastrointestinal hemorrhage. Secondary outcomes will include bleeding, antiplatelet replacement/discontinuation, health economic cost, utilization ratio of gastrointestinal-protective drugs, and MACE.
PROBLEM TO BE SOLVED: To obtain a moisturizing agent composition compatible with the skin, good in sense of use, having high moisture-keeping properties and useful for a cosmetic, a medicine for external use or the like by including a specific 1,3- dioxolan-2-one derivative. SOLUTION: This moisturizing agent composition contains a 1,3-dioxolan-2-one derivative of formula I [R1 is H, a 1-22C (un)saturated linear, branched or cyclic hydrocarbon or the like; R2 to R6 are each H or a 1-22C hydrocarbon], (e.g. 4-hydroxymethyl-1,3-dioxolan-2-one). Preferably, the amount of the formulated compound of formula I is generally 1-60 wt.%, especially 1-40 wt.%. The compound of formula I is obtained by alkylating a corresponding 4- hydroxymethyl-1,3-dioxolan-2-one. The compound of formula I wherein all of R2 to R6 are H is obtained by reacting a compound of formula II with dimethyl carbonate or diethyl carbonate in the presence of a basic catalyst.
The invention relates to two nickel acylhydrazone Schiff base complexes and a preparation method and application thereof. The invention aims to solve the problems of high cost, high cytotoxicity, easy generation of drug resistance of cells and the like of the existing platinum anticancer drugs. The molecular formulas of the two nickel complexes are respectively C 33 H 27 N 2 NiO 3 P and C 33 H 27 N 2 NiO 4 P, wherein the ligands are each o-incenseVanillin salicylhydrazone and o-vanillin benzoylhydrazone. The synthesis method comprises the following steps: two kinds of ligands and metal salt NiCl are respectively used 2 (PPh 3 ) 2 And Et 3 N is used as a raw material, ethanol/acetonitrile is used as a solvent, the mixture is fully reacted at a certain temperature, then cooled to room temperature, and the solvent is slowly volatilized to precipitate a target single crystal compound. The two nickel acylhydrazone complexes have obvious inhibition effect on human lung cancer cells and human breast cancer cells, and have certain effect on in-vitro free radical removal. Simple process, low cost, easy control of chemical components and the like, and has potential application value in the field of biological activity.
This randomised controlled trial (RCT) aims to examine the effectiveness of the Module-Based Psychological (MBP) intervention in reducing mental distress for youths in Hong Kong. This intervention study will be delivered in an individual format for 4 sessions of core module in 6 weeks plus/minus 2-3 sessions of tailored-made module in 3-4 weeks by frontline social or youth workers trained by professional clinicians. It is designed to improve the youths' abilities and skills in handling moods for better emotional management. The MBP intervention has two modules: core and tailor-made modules. The core module focuses on emotional management, while the five tailor-made modules include anxiety management, mood and depression management, anger management, sleeping well, and managing self-expectation and compassion. The tailor-made modules will be assigned to youths according to their needs. While the clinical outcome of the MBP is evaluated, its cost-effectiveness is also of particular concern. Planned interim analyses are built into the project for the sake of evaluation of the collected data from the ongoing trial, in which the primary research question is addressed and which has the potential to modify the conduct of the study. It is hypothesised that the youths who have received MBP intervention will demonstrate a greater reduction in mental distress, depressive symptoms, and anxiety symptoms compared to the youths in the waitlist control group. Besides, the MBP intervention will be more cost-effective than waiting.
OBJECTIVES: I. Compare the duration of chronic phase and survival following low- vs. high-dose interferon alfa maintenance therapy in patients with chronic myelogenous leukemia in chronic phase. II. Compare the toxicity profiles, assessed by WHO criteria, and the percentage of patients requiring dose reduction or discontinuation with these two regimens. III. Compare hematologic and cytogenetic responses every 6 months in patients treated on these two regimens.

OUTLINE: This is a randomized study. Patients receive daily hydroxyurea until their white blood cell count (WBC) is maintained at a normal level for 2-3 weeks. Patients are randomized to two groups: one group receives daily high-dose interferon alfa, and the other receives low-dose interferon alfa, 5 days per week. Both groups continue to receive hydroxyurea at reduced doses as needed to maintain a normal WBC. Treatment continues until disease progression occurs. Patients may receive cytarabine in addition to interferon in either treatment arm at the investigator's discretion. Cytarabine is given subcutaneously for 10 days every calendar month and continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 months for survival.

PROJECTED ACCRUAL: Approximately 800 patients will be enrolled over 8 years on this multicenter study.
PROBLEM TO BE SOLVED: To obtain solid cosmetics not giving dry or oily feeling and excellent in moist feeling by blending a specified powder and oil in a specific blending proportion and not having fluidity even in a heated state. SOLUTION: This solid cosmetics comprise 30-60wt.% porous powder and 40-70wt.% oil and do not have fluidity even heated at 100 deg.C for 5min. The porous powder is preferably used in 5-50wt.% content based on the total composition and preferably has >=200m<2> /g specific surface area and 3-30μm average particle diameter. A silica is especially preferred for the porous powder. A hydrophobic treatment or a water and oil repellent treatment of the powder can be performed. A lipid among cells is preferably blended in 0.1-90wt.% based on the oil component, when the lipid among cells is used as the oil component. Moreover, the cosmetics excellent in persistence of makeup and feeling in use is obtained by imparting a fluorine-based oil to the oil component. This solid cosmetics are effective in preventing a skin from drying and capable of keeping the skin fresh and young.